Based on the EEG model, age and LBM are significant demographic factors that must be considered when determining a dosage regimen for remifentanil. This remains true even when interindividual pharmacokinetic and pharmacodynamic variability are incorporated in the analysis.
No takes yet. Share an insight, caveat, or question.
Minto et al. (1997) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: